(Heidari Reza) - Shiraz University of Medical Sciences Pharmaceutical Sciences Research Center
(Niknahad Hossein) - Shiraz University of Medical Sciences Pharmaceutical Sciences Research Center
(Jamshidzadeh Akram) - Shiraz University of Medical Sciences Pharmaceutical Sciences Research Center
(Abdoli Narges) - Tabriz University of Medical Sciences Faculty of Pharmacy Department of Pharmacology and Toxicology
Abstract
Methimazole and propylthiouracil have been used in the management of hyperthyroidism for more than half a century. However, hepatotoxicity is one of the most deleterious side effects associated with these medications. The mechanism(s) of hepatic injury induced by antithyroid agents is not fully recognized yet. Furthermore, there are no specific tools for predicting the occurrence of hepatotoxicity induced by these drugs. The purpose of this article is to give an overview on possible susceptibility factors in liver injury induced by antithyroid agents. Age, gender, metabolism characteristics, alcohol consumption, underlying diseases, immunologic mechanisms, and drug interactions are involved in enhancing antithyroid drugs-induced hepatic damage. An outline on the clinically used treatments for antithyroid drugs-induced hepatotoxicity and the potential therapeutic strategies found to be effective against this complication are also discussed.
Å°¿öµå
Drug induced liver injury (DILI), Endocrinology, Hepatotoxicity, Idiosyncratic hepatic injury, Risk factors
KMID :
1103920140200030237
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)